These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23484133)

  • 1. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update.
    Guo Y; Lu N; Bai A
    Biomed Res Int; 2013; 2013():581631. PubMed ID: 23484133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab therapy for patients with inflammatory bowel disease: 10 years on.
    Van Assche G; Vermeire S; Rutgeerts P
    Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S17-25. PubMed ID: 19837056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
    Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
    J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.
    Lin MV; Blonski W; Buchner AM; Reddy KR; Lichtenstein GR
    Dig Dis Sci; 2013 Apr; 58(4):1149-56. PubMed ID: 23179145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.
    Afif W; Loftus EV; Faubion WA; Kane SV; Bruining DH; Hanson KA; Sandborn WJ
    Am J Gastroenterol; 2010 May; 105(5):1133-9. PubMed ID: 20145610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies in the management of inflammatory bowel disease.
    Rutgeerts P; Baert F
    Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses.
    Kanayama K; Nakamura K; Ogino H; Sumida Y; Ihara E; Akiho H; Takayanagi R
    Dig Dis Sci; 2011 Dec; 56(12):3525-33. PubMed ID: 21678051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [TNF-alpha inhibitors in inflammatory bowel disease].
    Casellas i Jordà F
    Med Clin (Barc); 2004 Nov; 123(16):627-34. PubMed ID: 15546523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
    Nakamura K; Honda K; Mizutani T; Akiho H; Harada N
    World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD.
    Dulai PS; Siegel CA; Peyrin-Biroulet L
    Gastroenterol Clin North Am; 2014 Sep; 43(3):441-56. PubMed ID: 25110252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biologics in current therapy for inflammatory bowel disease].
    Hisamatsu T; Hibi T
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Jun; 32(3):168-79. PubMed ID: 19564713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.
    Beigel F; Schnitzler F; Paul Laubender R; Pfennig S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Inflamm Bowel Dis; 2011 Jan; 17(1):91-8. PubMed ID: 20564536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
    Ben-Horin S; Yavzori M; Katz L; Kopylov U; Picard O; Fudim E; Coscas D; Bar-Meir S; Goldstein I; Chowers Y
    Gut; 2011 Jan; 60(1):41-8. PubMed ID: 20519742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of infliximab in inflammatory bowel disease.
    Hurd LB; Lichtenstein GR
    Gastroenterol Nurs; 1999; 22(5):199-208. PubMed ID: 10776108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.